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T he use of vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) among patients dependent on dialysis remains controversial. In this population, VKAs are associated with higher rates of major bleeding, particularly intracranial hemorrhage, and difficulty maintaining the international normalized ratio in the therapeutic range. A recent meta-analysis of 12 observational studies totaling 17 380 patients on hemodialysis (4010 of whom received VKAs) reported a nonsignificant reduction in the risk of ischemic stroke associated with VKAs (hazard ratio [HR] , 0.74; 95% CI, 0.51-1.06), an increase in total bleeding risk (HR, 1.21; 95% CI, 1.03-1.43), and a numeric near doubling of the risk for hemorrhagic stroke (4 studies; HR, 1.93; 95% CI, 0.93-3.98). 1 In addition to the lack of convincing efficacy and more concerning harm, warfarin has been implicated in the accelerated decline of renal function either through parenchymal microbleeds in the setting of excessive anticoagulation or vascular calcifications that result from its inhibition of the vitamin K cycle and γ-carboxylation of matrix Gla protein. 2, 3 Alternatives to VKAs are needed for this medically complex group of patients.
Randomized trials to date of apixaban versus warfarin for AF excluded patients with severe and end-stage kidney disease, calculated creatinine clearance <25 mL per minute. 4, 5 The US Food and Drug Administration cautiously extended apixaban use to patients with end-stage kidney disease on hemodialysis based on limited pharmacokinetic data. [6] [7] [8] The recommended dose of apixaban was 5 mg twice daily with a reduction in dose to 2.5 mg twice daily for either ≥80 years of age or body weight ≤60 kg. The expectation or hope was that the favorable results of the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) would be translated to patients with AF dependent on dialysis, specifically less major hemorrhage, less intracerebral hemorrhage, and lower mortality compared to VKAs. Rates of major bleeding among patients enrolled in the ARISTOTLE trial were 2.13% per year in the apixaban group compared with 3.09% per year in the warfarin group (HR, 0.69; 95% CI, 0.60-0.80).
In this issue of Circulation, Siontis et al 9 report their findings from a retrospective study of the use of apixaban versus warfarin among Medicare patients with AF identified in the US Renal Data System. Given the nonrandomized design, cohorts were matched using a prognostic score with patient factors derived from Medicare claims data. Drug exposure was determined using serial prescription refill data from Medicare Part D. Prespecified outcomes were determined from International Classification of Disease 9 and 10 codes in the primary or secondary diagnosis position of inpatient claims data. Bleeding was considered major if associated with a critical anatomic site, need for blood product transfusion during the same admission, or death. Laboratory values were not available.
In the apixaban group, 1034 (44%) patients were prescribed the standard dose (5 mg twice daily), and 1317 (56%) patients were prescribed the reduced dose (2.5 mg twice daily). In aggregate, apixaban was associated with less major bleeding compared with warfarin (HR, 0.72; 95% CI, 0.59-0.87), but no difference was found in stroke/systemic embolism, intracranial or gastrointestinal bleeding, or death. In matched cohorts of apixaban 5 mg twice daily and warfarin, apixaban was associated with statistically significant lower risks of incident stroke/systemic embolism (HR, 0.64; 95% CI, 0.42-0.97), major bleeding (HR, 0.71; 95% CI, 0.53-0.95), and death (HR, 0.63; 95% CI, 0.46-0.85). In matched cohorts of apixaban 2.5 mg twice daily and warfarin, apixaban was associated with lower risk of major bleeding (HR, 0.71; 95% CI, 0.56-0.91), but there were no differences for stroke/systemic embolism or death (HR, 1.11; 95% CI, 0.82-1.50). As stated, neither the standard nor reduced dose of apixaban was associated with significant differences for intracranial or gastrointestinal bleeding as compared with warfarin.
Although the results of this study are promising, some caution in interpretation is necessary because of the observational design and reliance on administrative data. Despite the use of statistical matching and multivariable models, unmeasured confounding is still a concern given that 56% of patients were prescribed the 2.5 mg dose. The patient characteristics that influenced physicians initially to choose apixaban or switch to apixaban from warfarin are unknown and given the lack of clinical data at the time to support its use. Based on the reported high percentage of patients prescribed the lower dose, clearly factors other than ≥80 years of age and weight of ≤60 kg drove selection of the lower dose.
The absolute rates of major bleeding are considerably higher than previously reported in this patient population-19.7% for apixaban and 22.9% for warfarin-and may in part reflect the methodology used to ascertain major hemorrhage. Inclusion of secondary diagnostic codes may have inflated the rates. Reliance on transfusion codes without a corroborating acute decrement in hemoglobin is also problematic because transfusions may be administered in the absence of active bleeding given the severe anemia characteristic of these patients. 10 Without review of source documents, it is difficult to reconcile the rates. Another potential source of bias involves hospital admission decisions influenced by out-of-range international normalized ratio values for patients treated with warfarin, a type of surveillance bias without corollary for apixaban.
Additional findings to highlight are the high discontinuation rates for both drugs (mean time on apixaban 105 days, warfarin 157 days) and the lack of advantage of apixaban versus warfarin in terms of intracerebral hemorrhage. Given the high prevalence of cerebral microbleeds in the dialysis population, it was hoped that apixaban would confer some degree of reduced risk of this complication, as was evident in the ARISTOTLE trial. 4, 11, 12 However, this finding may be spurious for several reasons: unmeasured confounding between the groups, whereby those patients thought to be at highest risk of intracerebral hemorrhage were preferentially prescribed apixaban; event determination from billing codes without review of source documents to validate primary hemorrhage and location of hemorrhage; drug exposure extrapolated from pharmacy data without any measure of drug adherence, and sample size of the study inadequate to meaningfully address the question.
Several randomized trials are currently underway to definitively assess the treatment effects of apixaban compared with VKAs in the population dependent on dialysis. The RENAL-AF (Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation) will randomize patients to apixaban 5 mg twice daily versus warfarin with an international normalized ratio of 2-3. 13 The lower 2.5 mg twice daily dose will be assigned for selected patients. The primary end point is time to first bleeding event using the International Society of Thrombosis and Haemostasis definition of major hemorrhage, as was used in the AF trials.
14 In addition, the AXADIA study (Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation and End-Stage Kidney Disease) ( will randomize patients to apixaban 2.5 mg twice daily versus phenprocoumon. 15 The randomization of study drug and blinded event adjudication in these trials will help to minimize bias and confounding, and will better elucidate the risks and benefits of standard versus low-dose apixaban. Neither of these trials will be adequately powered to address the important questions relating to intracerebral hemorrhage.
If the results reported by Siontis and colleagues 9 are confirmed (reduced stroke, reduced major bleeding, reduced mortality), standard dose apixaban will be the preferred anticoagulant for stroke prevention in AF among patients dependent on dialysis. However, if the high rates of major and intracerebral bleeding and drug discontinuation are also confirmed, then little progress has actually been made, and the viability of anticoagulation for stroke prevention in this medically complex patient population will remain in question.
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